Ultima-Selank 10mg

MANUFACTURER Ultima Pharmaceuticals - US
WAREHOUSE USA Warehouse 5
SUBSTANCE Selank

Your product will be shipped without brand labels for enhanced security.

The burgeoning field of biotechnology has opened doors to exploring innovative biologically active compounds, including the exciting category of "cognitive enhancers" or "nootropics." Among these is Selank, previously known as "TP-7," a synthetic peptide meticulously engineered for superior performance.

Marketed as an effective ?anti-anxiety? solution, Selank is also credited with boosting learning capabilities and energy levels?allegedly without any side effects or addiction risks. This compact molecule is significantly smaller than most natural proteins and was developed through a collaboration between the Institute of Molecular Genetics (part of the Russian Academy of Sciences) and the V.V. Zakusov Research Institute of Pharmacology, alongside its counterpart, Semax.

Selank is a fusion of a naturally occurring peptide called tuftsin and a sequence that enhances its stability. Tuftsin is integral to the natural antibody IgG.

Research indicates both tuftsin and Selank may lower anxiety and elevate serotonin levels in rats, with Selank demonstrating slightly superior effectiveness.

In Russia, Selank is approved for treating generalized anxiety disorder (GAD) and is recognized for its nootropic benefits. Although it lacks FDA approval for medical conditions in the U.S., Selank remains readily available in several countries, often labeled as a ?nutritional supplement.?

The precise mechanisms of Selank's action are not fully elucidated. It is thought to partially stabilize enkephalins in the bloodstream, natural peptides that help combat stress responses. However, studies on mice have not confirmed enkephalin stabilization or significant anti-anxiety effects following Selank administration.

Evidence suggests that Selank may interact with GABA receptors, which are linked to sedative effects. In one study, Selank-treated mice exhibited increased activity in GABA-dependent inhibitory neurons, correlating with reduced overall brain activity, consistent with sedative properties.

Furthermore, some studies indicate Selank may elevate BDNF levels, a critical neurotrophic factor associated with learning and memory, potentially explaining some of its claimed cognitive benefits.

Research also hints that Selank could influence neurotransmitter levels, such as norepinephrine, dopamine, and serotonin, which are crucial for motivation, focus, and pleasure. However, findings have varied, with one study indicating Selank may increase norepinephrine while decreasing dopamine and serotonin. Another reported rises in both norepinephrine and dopamine without affecting serotonin, leaving the exact effects of Selank somewhat unclear.

In a preliminary clinical trial involving 62 participants, those administered Selank observed a reduction in anxiety symptoms, particularly among individuals with anxiety disorders. Another study with 60 patients suffering from anxiety and phobias yielded similar results, with benefits lasting up to a week post-treatment.

Additionally, a further study on 70 anxiety patients revealed that Selank enhanced the effects of phenazepam, a restricted anti-anxiety medication in the U.S., while mitigating negative side effects such as drowsiness and memory loss. Animal studies also support these findings, showing significant anti-anxiety effects in the most anxious subjects following Selank treatment.

While evidence remains limited, these promising results indicate Selank may help alleviate anxiety. However, it is crucial to consult a healthcare provider before considering Selank, ensuring it does not replace prescribed treatments.

One study suggested that Selank stabilizes memory traces, potentially enhancing retention in rats over a 30-day period. However, the methodology for assessing these effects remains ambiguous. Another study noted Selank's potential to preserve memory in monkeys, yet adequate human studies are lacking to confirm its efficacy and safety for healthy individuals.

In a notable study, Selank administration in rats with toxin-induced brain damage restored their brain activity to normal levels.

Research has shown that Selank can reduce depression symptoms, as evidenced by reduced immobility in a forced swimming test in mice, with lower doses proving more effective than higher ones.

Preliminary animal studies indicate that Selank injections may boost antioxidant levels in the livers of stressed mice.

A study involving sedated cats revealed that Selank could lower blood pressure by approximately 30% for up to three minutes, while enhancing cerebral blood flow by around 24% for up to 10 minutes. However, these short-term effects raise questions about their clinical significance, particularly since findings are limited to animal models and their relevance to human health is uncertain.

Considering that anxiety is a common symptom of alcohol withdrawal, a study where rats were given a 10% ethanol solution for 24 weeks found that those treated with Selank experienced reduced anxiety following a 48-hour withdrawal period.

In a study, rats on a high-fat diet gained 35% less weight while treated with Selank, with total cholesterol levels dropping over 58% and blood glucose levels decreasing by 23.5%.

In an animal model involving breast cancer, mice treated with Selank daily exhibited slower tumor growth and longer survival rates compared to untreated counterparts. However, these preliminary findings do not suggest Selank as a viable cancer therapy; extensive further research is necessary to explore any medicinal applications, and it should never replace standard cancer treatments.

After Selank treatment, various inflammatory response genes were identified in the spleens of mice, hinting at potential protective effects against inflammation.

Research indicates that Selank can reduce the size of stomach ulcers in animal studies, with hypotheses suggesting this may be due to increased lymph flow to the stomach. Nonetheless, further comprehensive human studies are necessary to validate these findings and understand the underlying mechanisms.

Selank has been observed to elevate IL-6 levels in the blood cells of depressed patients, with IL-6 being an inflammatory protein that aids in fighting infections. Additionally, a cell-based study suggested that Selank might stimulate interferon release, known for its anti-viral properties. However, a mouse study infected with a virus found no anti-viral benefits from Selank, casting doubt on this potential application.